Lack of research data and failure to consider patients’ functional age affects how older adults with breast cancer are managed.
Researchers found that age and tumor size were the most significant factors for predicting renal cell carcinoma (RCC).
Single bundle payments may be as effective for treatment, and much less expensive, than fee-for-service programs in health care.
Prostate-specific antigen screening is not meaningfully less frequent than before guidelines were issued against use of the test.
Newly-discovered and future biomarkers are likely to help oncologists give an accurate prognosis and to prescribe more effective treatment for patients with multiple myeloma.
Immunotherapy may be effective for some patients with NSCLC as a second-line treatment, but it’s unclear the role it will have in the first-line.
It is the responsibility of investigators to develop randomized trials that investigate rare subtypes of RCC, according to an editorial.
MSKCC is teaming up with Medidata to test the use of wearable activity trackers among patients with multiple myeloma undergoing treatment for their disease.
Local treatment may provide a survival benefit for patients with metastatic non-small cell lung cancer (NSCLC).
The oral VEGF receptor TKI cabozantinib significantly improved overall survival, delayed disease progression, and improved objective response in renal cell carcinoma (RCC).
